These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 8320630

  • 21. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents.
    Hodder SL, Cherry JD, Mortimer EA, Ford AB, Gornbein J, Papp K.
    Clin Infect Dis; 2000 Jul; 31(1):7-14. PubMed ID: 10913389
    [Abstract] [Full Text] [Related]

  • 22. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A, Bona G, Canciani G, Pistilli AM, Contu B, Furlan R, Meloni T, Stramare D, Titone L, Rappuoli R.
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [Abstract] [Full Text] [Related]

  • 23. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
    Hendrikx LH, Schure RM, Oztürk K, de Rond LG, de Greeff SC, Sanders EA, Berbers GA, Buisman AM.
    Vaccine; 2011 Sep 16; 29(40):6874-80. PubMed ID: 21803088
    [Abstract] [Full Text] [Related]

  • 24. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children.
    Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd AM, Litteer T.
    Pediatr Infect Dis J; 1994 Mar 16; 13(3):193-6. PubMed ID: 8177626
    [Abstract] [Full Text] [Related]

  • 25. Household contact study of Bordetella pertussis infections.
    Deen JL, Mink CA, Cherry JD, Christenson PD, Pineda EF, Lewis K, Blumberg DA, Ross LA.
    Clin Infect Dis; 1995 Nov 16; 21(5):1211-9. PubMed ID: 8589145
    [Abstract] [Full Text] [Related]

  • 26. Serum anti-PT and anti-FHA antibody levels, and agglutinin titers after administration of acellular pertussis vaccines.
    Kuno-Sakai H, Kimura M, Sato Y, Tsunoda A, Urano T, Isomura S, Kamiya H.
    Acta Paediatr Jpn; 1989 Apr 16; 31(2):120-6. PubMed ID: 2516691
    [Abstract] [Full Text] [Related]

  • 27. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
    Wood N, Marshall H, White OJ, Holt PG, McIntyre P.
    Pediatr Infect Dis J; 2014 May 16; 33(5):511-7. PubMed ID: 24445839
    [Abstract] [Full Text] [Related]

  • 28. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ, Han SB, Kim BR, Kang KR, Huh DH, Choi GS, Ahn DH, Kang JH.
    BMC Infect Dis; 2017 Apr 04; 17(1):247. PubMed ID: 28376777
    [Abstract] [Full Text] [Related]

  • 29. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
    Cropley I, Douce G, Roberts M, Chatfield S, Pizza M, Marsili I, Rappuoli R, Dougan G.
    Vaccine; 1995 Dec 04; 13(17):1643-8. PubMed ID: 8719514
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
    Kimura M, Kuno-Sakai H, Kamiya H, Ueda K, Isomura S, Koike M, Kato T, Ozaki T, Hirose M, Egami T.
    Acta Paediatr Jpn; 1995 Oct 04; 37(5):562-74. PubMed ID: 8533580
    [Abstract] [Full Text] [Related]

  • 35. Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013-2017.
    Xu Z, Octavia S, Luu LDW, Payne M, Timms V, Tay CY, Keil AD, Sintchenko V, Guiso N, Lan R.
    Emerg Infect Dis; 2019 Jun 04; 25(6):1196-1199. PubMed ID: 31107218
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Western blot analysis of antibody responses of young infants to pertussis infection.
    Guiso N, Grimprel E, Anjak I, Bégué P.
    Eur J Clin Microbiol Infect Dis; 1993 Aug 04; 12(8):596-600. PubMed ID: 8223658
    [Abstract] [Full Text] [Related]

  • 39. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
    Thomas MG, Ashworth LA, Miller E, Lambert HP.
    J Infect Dis; 1989 Nov 04; 160(5):838-45. PubMed ID: 2572651
    [Abstract] [Full Text] [Related]

  • 40. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM, Lee CY, Lin TY, Chen JM, Lee PI, Hsu CY.
    Vaccine; 1996 Jun 04; 14(9):916-22. PubMed ID: 8843635
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.